H.C. Wainwright analyst Emily Bodnar maintained a Buy rating on Jasper Therapeutics today and set a price target of $20.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Emily Bodnar’s rating is based on Jasper Therapeutics’ promising clinical trial results and ongoing developments. The company has shown encouraging data from its BEACON trial, particularly with the briquilimab drug, which has demonstrated a high complete response rate in patients, even when inactive drug product was used. This suggests a strong efficacy profile compared to competitors.
Additionally, the company’s efforts to address and investigate any issues related to drug administration and patient selection indicate a proactive approach to ensuring the success of their clinical trials. The anticipation of further data updates in the coming quarters, alongside the consistent positive efficacy signals in higher dose cohorts, supports the Buy rating as these factors collectively highlight the potential for Jasper Therapeutics to achieve positive outcomes in the future.